225 Second Avenue
About BioverativLaunching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.
CEO: John Cox
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.